4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

4 - Liquidia Corp (0001819576) (Issuer)

Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy

Raymond James initiated coverage of Liquidia Technologies with a rating of Outperform and set a new price target of $27.00

Oppenheimer initiated coverage of Liquidia Technologies with a rating of Perform

Needham reiterated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $28.00 from $18.00 previously

Wedbush resumed coverage of Liquidia Technologies with a rating of Underperform and set a new price target of $3.00

Wedbush downgraded Liquidia Technologies from Neutral to Underperform and set a new price target of $3.00

Ladenburg Thalmann initiated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $15.00

MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation's request for a preliminary injunction and temporary restraining order in its complaint filed against Liquidia and the first commercial sale of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Liquidia's Chief Financial

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics' request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This m

MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will b

FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effortDemonstrated tolerability and titratability in the pivotal INSPIRE studyLiquidia will host a webcast Tuesday, May 27, 2025 at 8:30 a.m. ET to provide an update on commercial launch preparations MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the U.S. Food and Drug Administration (FDA) has appro

New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR's ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent claims same general subject matter as UTHR's invalidated ‘793 patentDoes not impact FDA's ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. Distr

Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will

MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company's Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-pre

Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia's amendment to its New Drug Application (NDA) for YUTREPIA™ (t

MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will be available on Liquidia's website for at least 30 d

SCHEDULE 13G - Liquidia Corp (0001819576) (Subject)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

10-Q - Liquidia Corp (0001819576) (Filer)

8-K - Liquidia Corp (0001819576) (Filer)

MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora

MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and ot

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension

MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertensio

MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and

MORRISVILLE, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the third quarter 2022 financial results and provide a corporate update. Roger Jeffs, Liquidia's Chief Executive Officer, said: "The third quarter marked a critical juncture in our mission to provide YUTREPIA™ (treprostinil) inhalation powder to patients with PAH and PH-ILD. We have now demonstrated in at least one legal forum that each of the patent claims asserted against us is invalid or not infringed. We will co

MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 7467713. A webcast of the call will be available and archived for 30 days on Liquidia's website at https://liquidia.com/index.php/investors/events-and-presentations. About Liquidia CorporationLiquidia Corporation is a biopharma

District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patentAll patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB)PTAB decision to invalidate all claims of ‘793 patent is not affectedAbility to seek final FDA approval of YUTREPIA™ (treprostinil) inhalation powder is contingent on affirmation of the PTAB decision or reversal of District Court decision regarding the ‘793 patent MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United Therapeu

SC 13G/A - Liquidia Corp (0001819576) (Subject)

SC 13D/A - Liquidia Corp (0001819576) (Subject)

SC 13D/A - Liquidia Corp (0001819576) (Subject)

SC 13G/A - Liquidia Corp (0001819576) (Subject)

SC 13G/A - Liquidia Corp (0001819576) (Subject)

SC 13G - Liquidia Corp (0001819576) (Subject)

SC 13G - Liquidia Corp (0001819576) (Subject)

SC 13D/A - Liquidia Corp (0001819576) (Subject)

SC 13G - Liquidia Corp (0001819576) (Subject)

SC 13G/A - Liquidia Corp (0001819576) (Subject)

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022. Roger Jeffs, Chief Executive Officer of Liquidia, said: "We are excited to add a leader of Dr. Saggar's caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval. His expertise and credibility in treating patients across a wid

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition. “After an extensive search and thorough review of many outstanding candidates, it is with great pleasure that, today, we welcome Mike Kaseta to the Liquidia team,” said Neal Fowler, Chief Executive Officer at Liquidia. “I am confident that Mike’s financial expertise, business acu